Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2/Neu Positive Clear all
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Aitkin, Minnesota • Baxter, Minnesota • Brainerd, Minnesota + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
Interventions
BDC-1001, Nivolumab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions
Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
Combination Product · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
32
States / cities
Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Anastrozole, Surgical resection of breast tumor
Drug · Procedure
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Taselisib, Placebo, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
16
States / cities
Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab (drug), Herceptin (drug)
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
18
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumors, Breast Cancer
Interventions
Tanespimycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Interventions
Tesevatinib, Trastuzumab
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Fulvestrant
Drug
Lead sponsor
Nancy Chan, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
218
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Taxol, Adriamycin, Cytoxan
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced May 21, 2026, 6:32 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer
Interventions
Almac HER-Seq Assay
Diagnostic Test
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
DiviTum® TKa assay, Study Care Plans
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
ribociclib (LEE011), Exemestane, Everolimus (RAD001)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
8
States / cities
Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions
BKM120, Trastuzumab, Capecitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced May 21, 2026, 6:32 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
87
States / cities
Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancers With HER2 Expression
Interventions
BAY2701439
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
HER2-positive Breast Cancer, ER-positive Breast Cancer
Interventions
fulvestrant 500 mg, Docetaxel, Trastuzumab (H, 8mg/kg, Pertuzumab (P, 840 mg
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced May 21, 2026, 6:32 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Agendia
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Palm Springs, California • Miami, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 6:32 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Triple Negative Breast Cancer, Early-stage Breast Cancer, HER2-positive Breast Cancer
Interventions
Neratinib
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced May 21, 2026, 6:32 PM EDT